Tag: Epicutaneous Immunotherapy (EPIT)

Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in...

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Moonlight Therapeutics Microneedle Patch

Study Finds Microneedle Delivery Successful in Test of Peanut Allergy Immunotherapy

Study finds five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch.
Viaskin Patch

Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...

The patch therapy remains in regulatory limbo.
Viaskin-Patch

Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study

Reactions decreased over study duration.
Viaskin Peanut

FDA Wants More Viaskin Peanut Data Resulting in Further Approval Delays

Delays mount pushing trials of modified patch.
Moonlight Therapeutics Microneedle Patch

New Microneedle Patch Therapy for Food Allergies Takes Step Forward

Painless microneedle patch may provide new method for desensitization.
DBV Patch Closeup

DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...

The company announced they would be laying off 200 employees in Q1.